Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of AVEO Pharmaceuticals, Inc. Business Wire SAN DIEGO -- May 2, 2013 Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of AVEO Pharmaceuticals, Inc (NASDAQ: AVEO) violated state or federal laws when recently communicating their outlook for AVEO’s anticipated FDA approval of tivozanib. According to Johnson & Weaver, LLP, shares of AVEO declined more than 58% in early trading on Thursday, May 2, 2013, after Members of the Food and Drug Administration advisory panel rejected approval for AVEO’s drug tivozanib by a vote of 13-1. The FDA panel specifically criticized AVEO for relying on a single-final phase clinical trial and stated that the company should conduct another study to better assess the benefits. Johnson & Weaver’s investigation is ongoing, with particular focus on whether AVEO management misrepresented tivozanib’s clinical trial results or prospects for FDA approval. Jim Baker, Lead Analyst for Johnson & Weaver, stated that, "It is quite peculiar that AVEO was banking on this limited trial information to boast about the potential FDA approval.” If you have information that could assist in this investigation or if you are an AVEO shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (firstname.lastname@example.org)by email or by phone at 619-230-0063. Johnson & Weaver, LLP is a nationally recognized shareholders’ rights law firm. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Contact: Johnson & Weaver, LLP Jim Baker 619-230-0063, Ext. 118 email@example.com
Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of AVEO Pharmaceuticals, Inc.
Press spacebar to pause and continue. Press esc to stop.